1.5 Abstract in rivista

1.5 Abstract in rivista: [2299] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 641 a 660 di 2.299

Prospective MRI study in pediatric thalassemia major (TM) patients in the MIOT network: a tool to strengthen medical decisions

2014 Casale, Maddalena; Meloni, A; Cuccia, L; D’Ascola, D; Caruso, V; Quarta, A; Putti, Mc; Tudisca, C; Filosa, A; Pepe, A.

Association between serum ferritin and liver iron concentration with cardiac iron in pediatric thalassemia major patients

2016 Meloni, A; Casale, Maddalena; Filosa, A; Neri, Mg; Pitrolo, L; Smacchia, Mp; Renne, S; Vallone, A; Positano, V; Pepe, A.

Longitudinal Prospective MRI Study in Pediatric Patients With Thalassemia Major

2017 Casale, Maddalena; Meloni, A.; Filosa, A.; Pistoia, L.; Sorrentino, F.; Quarta, A.; Carollo, A.; Cirotto, M. C.; Positano, V.; Grassedonio, E.; Missere, M.; Pepe, A.

Resveratrol attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of doxorubicin cardiomyopathy

2016 Cappetta, D; Esposito, G; Piegari, Elena; Russo, R; Ciuffreda, Lp; Rivellino, A; Berrino, Liberato; Rossi, Francesco; DE ANGELIS, Antonella; Urbanek, K.

Dipeptidyl peptidase 4 inhibitor sitagliptin reduces oxidative stress, endothelial dysfunction and preserves diastolic function in a rat model of heart failure with preserved ejection fraction

2016 Urbanek, K; Cappetta, D; Piegari, Elena; Esposito, G; Russo, R; Ciuffreda, Lp; Rivellino, A; Berrino, Liberato; Rossi, Francesco; DE ANGELIS, Antonella

Diurnal time course of sleepiness in Italian junior and high school students

2016 Cerasuolo, M; Arzilli, C; Conte, F; Giganti, F; Ficca, Gianluca

A methodology to awake citizens' awareness on the effects of leisure noise

2017 Maffei, Luigi; Masullo, Massimiliano; Ciaburro, Giuseppe; D'Onofrio, L.

A Unique Myopathy Syndrome in a Patient Disclosing Clinical, Laboratory, and Genetic Findings of Late-Onset Pompe Disease, Together with a Lack of Dysferlin on Muscle Biopsy

2015 Sampaolo, Simone; Lombardi, Luca; Pascarella, Angelo; Picillo, Esther; Farina, Olimpia; Esposito, Teresa; Politano, Luisa; DI IORIO, Giuseppe

18. Imapired excerise performance in systemic sclerosis. Clinical correlations

2008 Valentini, G.; Santoriello, C.; Cuomo, Giovanna; Polverino, F.; Ruocco, L.; Polverino, M. .

[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes

2009 Abignano, G.; Iudici, M.; Petrillo, A.; Cuomo, Giovanna; Valentini, Gabriele

TWENTYFOUR-MONTH AZATHIOPRINE AS MAINTENANCE THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE TREATED WITH LOW DOSE CYCLOPHOSPHAMIDE PULSE THERAPY

2009 Abignano, G.; Cuomo, Giovanna; Iudici, M.; Petrillo, A.; Valentini, G.

[FRI0311] CORRELATIONS BETWEEN CLINICAL FEATURES OF154 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND SHORT FORM36 (SF36) SCORES G. Cuomo, M. Iudici, G. Abignano, A. Petrillo, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Background: The quality of life is reduced in patients with systemic sclerosis (SSc) as evaluated by both disease specific (HAQ-DI; SHAQ) or generic questionnaires. The correlations between SF-36 scores and some disease features have not yet been explored. Objectives: To evaluate the relationships between health values as evaluated by SF-36 and clinical features in SSc patients. Methods: From 9/01/07 to 8/31/08 154 consecutive SSc patients (144 females; 10 males); aged from 20–82 years (median age 54), with disease duration from 1-47 years (median 10,5 years); attending the outpatient clinic of the Rheumatology Unit of Second University of Naples, were enrolled in the study. The scores of the eight areas of SF-36 General Health: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social function (SF), Role Emotional (RE) and Mental Health (MH), were evaluated in the range of 0–100, the higher values reflecting a better Quality of life (Qol). In addition two global series i.e. the Physical Component Summary Score (PCS) and the Mental Component Summary Score (MCS) were calculated. The patients were also investigated for disease subset (limited or diffuse); skin involvement by the modified Rodnan skin score; disability by HAQ-DI; disease activity by European Activity Index, and disease severity by Medsger severity scale. Results: SF36 score did not differ between the 31 patients with diffuse vs the 123 with limited disease All the items of SF36 were significantly correlated to activity Index (Rho from –0.28 to -0.32: p<0.0001) and HAQ-DI (Rho from -0.38 to -0.82: p<0.0001). GH resulted to correlate with mRss (Rho -0.17; p<0.05) The significant correlations between each item of the Medsger's severity scale and each item of SF36 are reported in table. PF RP BP GH VT SF RE MH PCS/MCS Sev_Gen (Rho) – – – – – – – – –/– Sev_Vasc(Rho) – – – – – – – – –/– Sev_Skin (Rho) – – – – – – – – –/– Sev_Joint (Rho) – – – -0.18* – – – – -0.21/– Sev_muscle (Rho) -0.25 – – -0.16* -0.18* -0.22* – -0.20* -0.20/– Sev_GI (Rho) -0.20 – – -0.22 – – – – –/– Sev_lung (Rho) -0.28* – – -0.23** -0.17* -0.23 -0.22 – -0.19/– Sev_Heart (Rho) – – -0.22 – – – – – -0.21/– Sev_kidney (Rho) – – – – – – – – – p<0.05; p<0.001; *p<0.0001. Conclusion: The present study, confirms that the Health Value, as evaluated by SF36, is diminished in SSc. Our study point out a previously univestigated correlation between SF-36 scores and disease activity. Disclosure of Interest: NONE declared Ann Rheum Dis 2009;68(Suppl3):459 Session: Scleroderma, myositis and related syndromes

2009 Cuomo, Giovanna; Iudici, M.; Abignano, G.; Petrillo, A.; Valentini, G.

MYCOPHENOLATE MOFETIL IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS

2009 Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G. .

AUTOANTIBODIES AND CLINICAL FEATURES CAN PREDICT EVOLUTION IN PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE (MCTD)

2011 Cappelli, S.; Bellando Randone, S.; Martinovic, D.; Tamas, M. M.; Pasalic, K.; Allanore, Y.; Mosca, M.; Talarico, R.; Opris, D.; Kiss, C.; Tausche, A. K.; Cardarelli, S.; Riccieri, V.; Koneva, O.; Cuomo, Giovanna; Becker, M. O.; Sulli, A.; Guiducci, S.; Radic, M.; Bombardieri, S.; Aringer, M.; Cozzi, F.; Valesini, G.; Ananieva, L.; Valentini, G.; Riemekasten, G.; Cutolo, M.; Ionescu, R.; Czirják, L.; Damjanov, N.; Rednic, S.; Matucci Cerinic, M.

ARTICULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC). ULTRASONOGRAPHIC FEATURES OF HAND JOINTS

2009 Cuomo, Giovanna; Zappia, M.; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G.

THE ROLE OF HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) IN PREDICTING SURVIVAL IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS (SSC)

2011 Iudici, M.; Cuomo, Giovanna; D'Abrosca, V.; Irace, R.; Valentini, G.

COURSE OF HBV INFECTION IN PATIENTS UNDERGOING TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)

2011 Urraro, T.; Cuomo, Giovanna; Valentini, G.

HYPOCOMPLEMENTEMIA IN SYSTEMIC SCLEROSIS (SSC)

2008 Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Valentini, G.

CLINICAL AND SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS

2007 Vettori, Serena; Abbadessa, Salvatore; Chiarolanza, I.; Ruocco, L.; Cuomo, Giovanna; Maresca, L.; Leonardo, G.; Valentini, G.

ELF TEST: A PROMISING SURROGATE OUTCOME MEASURE IN SYSTEMIC SCLEROSIS

2011 G., Abignano; Cuomo, Giovanna; Buch, M.; Rosenberg, W. M.; Valentini, G.; Emery, P.

Titolo	Data di pubblicazione	Autore(i)
Prospective MRI study in pediatric thalassemia major (TM) patients in the MIOT network: a tool to strengthen medical decisions	1-gen-2014	Casale, Maddalena; Meloni, A; Cuccia, L; D’Ascola, D; Caruso, V; Quarta, A; Putti, Mc; Tudisca, C; Filosa, A; Pepe, A.
Association between serum ferritin and liver iron concentration with cardiac iron in pediatric thalassemia major patients	1-gen-2016	Meloni, A; Casale, Maddalena; Filosa, A; Neri, Mg; Pitrolo, L; Smacchia, Mp; Renne, S; Vallone, A; Positano, V; Pepe, A.
Longitudinal Prospective MRI Study in Pediatric Patients With Thalassemia Major	1-gen-2017	Casale, Maddalena; Meloni, A.; Filosa, A.; Pistoia, L.; Sorrentino, F.; Quarta, A.; Carollo, A.; Cirotto, M. C.; Positano, V.; Grassedonio, E.; Missere, M.; Pepe, A.
Resveratrol attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of doxorubicin cardiomyopathy	1-gen-2016	Cappetta, D; Esposito, G; Piegari, Elena; Russo, R; Ciuffreda, Lp; Rivellino, A; Berrino, Liberato; Rossi, Francesco; DE ANGELIS, Antonella; Urbanek, K.
Dipeptidyl peptidase 4 inhibitor sitagliptin reduces oxidative stress, endothelial dysfunction and preserves diastolic function in a rat model of heart failure with preserved ejection fraction	1-gen-2016	Urbanek, K; Cappetta, D; Piegari, Elena; Esposito, G; Russo, R; Ciuffreda, Lp; Rivellino, A; Berrino, Liberato; Rossi, Francesco; DE ANGELIS, Antonella
Diurnal time course of sleepiness in Italian junior and high school students	1-gen-2016	Cerasuolo, M; Arzilli, C; Conte, F; Giganti, F; Ficca, Gianluca
A methodology to awake citizens' awareness on the effects of leisure noise	1-gen-2017	Maffei, Luigi; Masullo, Massimiliano; Ciaburro, Giuseppe; D'Onofrio, L.
A Unique Myopathy Syndrome in a Patient Disclosing Clinical, Laboratory, and Genetic Findings of Late-Onset Pompe Disease, Together with a Lack of Dysferlin on Muscle Biopsy	1-gen-2015	Sampaolo, Simone; Lombardi, Luca; Pascarella, Angelo; Picillo, Esther; Farina, Olimpia; Esposito, Teresa; Politano, Luisa; DI IORIO, Giuseppe
18. Imapired excerise performance in systemic sclerosis. Clinical correlations	1-gen-2008	Valentini, G.; Santoriello, C.; Cuomo, Giovanna; Polverino, F.; Ruocco, L.; Polverino, M. .
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes	1-gen-2009	Abignano, G.; Iudici, M.; Petrillo, A.; Cuomo, Giovanna; Valentini, Gabriele
TWENTYFOUR-MONTH AZATHIOPRINE AS MAINTENANCE THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE TREATED WITH LOW DOSE CYCLOPHOSPHAMIDE PULSE THERAPY	1-gen-2009	Abignano, G.; Cuomo, Giovanna; Iudici, M.; Petrillo, A.; Valentini, G.
[FRI0311] CORRELATIONS BETWEEN CLINICAL FEATURES OF154 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND SHORT FORM36 (SF36) SCORES G. Cuomo, M. Iudici, G. Abignano, A. Petrillo, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Background: The quality of life is reduced in patients with systemic sclerosis (SSc) as evaluated by both disease specific (HAQ-DI; SHAQ) or generic questionnaires. The correlations between SF-36 scores and some disease features have not yet been explored. Objectives: To evaluate the relationships between health values as evaluated by SF-36 and clinical features in SSc patients. Methods: From 9/01/07 to 8/31/08 154 consecutive SSc patients (144 females; 10 males); aged from 20–82 years (median age 54), with disease duration from 1-47 years (median 10,5 years); attending the outpatient clinic of the Rheumatology Unit of Second University of Naples, were enrolled in the study. The scores of the eight areas of SF-36 General Health: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social function (SF), Role Emotional (RE) and Mental Health (MH), were evaluated in the range of 0–100, the higher values reflecting a better Quality of life (Qol). In addition two global series i.e. the Physical Component Summary Score (PCS) and the Mental Component Summary Score (MCS) were calculated. The patients were also investigated for disease subset (limited or diffuse); skin involvement by the modified Rodnan skin score; disability by HAQ-DI; disease activity by European Activity Index, and disease severity by Medsger severity scale. Results: SF36 score did not differ between the 31 patients with diffuse vs the 123 with limited disease All the items of SF36 were significantly correlated to activity Index (Rho from –0.28 to -0.32: p<0.0001) and HAQ-DI (Rho from -0.38 to -0.82: p<0.0001). GH resulted to correlate with mRss (Rho -0.17; p<0.05) The significant correlations between each item of the Medsger's severity scale and each item of SF36 are reported in table. PF RP BP GH VT SF RE MH PCS/MCS Sev_Gen (Rho) – – – – – – – – –/– Sev_Vasc(Rho) – – – – – – – – –/– Sev_Skin (Rho) – – – – – – – – –/– Sev_Joint (Rho) – – – -0.18* – – – – -0.21/– Sev_muscle (Rho) -0.25 – – -0.16* -0.18* -0.22* – -0.20* -0.20/– Sev_GI (Rho) -0.20 – – -0.22 – – – – –/– Sev_lung (Rho) -0.28* – – -0.23** -0.17* -0.23 -0.22 – -0.19/– Sev_Heart (Rho) – – -0.22 – – – – – -0.21/– Sev_kidney (Rho) – – – – – – – – – p<0.05; p<0.001; *p<0.0001. Conclusion: The present study, confirms that the Health Value, as evaluated by SF36, is diminished in SSc. Our study point out a previously univestigated correlation between SF-36 scores and disease activity. Disclosure of Interest: NONE declared Ann Rheum Dis 2009;68(Suppl3):459 Session: Scleroderma, myositis and related syndromes	1-gen-2009	Cuomo, Giovanna; Iudici, M.; Abignano, G.; Petrillo, A.; Valentini, G.
MYCOPHENOLATE MOFETIL IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS	1-gen-2009	Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G. .
AUTOANTIBODIES AND CLINICAL FEATURES CAN PREDICT EVOLUTION IN PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE (MCTD)	1-gen-2011	Cappelli, S.; Bellando Randone, S.; Martinovic, D.; Tamas, M. M.; Pasalic, K.; Allanore, Y.; Mosca, M.; Talarico, R.; Opris, D.; Kiss, C.; Tausche, A. K.; Cardarelli, S.; Riccieri, V.; Koneva, O.; Cuomo, Giovanna; Becker, M. O.; Sulli, A.; Guiducci, S.; Radic, M.; Bombardieri, S.; Aringer, M.; Cozzi, F.; Valesini, G.; Ananieva, L.; Valentini, G.; Riemekasten, G.; Cutolo, M.; Ionescu, R.; Czirják, L.; Damjanov, N.; Rednic, S.; Matucci Cerinic, M.
ARTICULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC). ULTRASONOGRAPHIC FEATURES OF HAND JOINTS	1-gen-2009	Cuomo, Giovanna; Zappia, M.; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G.
THE ROLE OF HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) IN PREDICTING SURVIVAL IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS (SSC)	1-gen-2011	Iudici, M.; Cuomo, Giovanna; D'Abrosca, V.; Irace, R.; Valentini, G.
COURSE OF HBV INFECTION IN PATIENTS UNDERGOING TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)	1-gen-2011	Urraro, T.; Cuomo, Giovanna; Valentini, G.
HYPOCOMPLEMENTEMIA IN SYSTEMIC SCLEROSIS (SSC)	1-gen-2008	Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Valentini, G.
CLINICAL AND SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS	1-gen-2007	Vettori, Serena; Abbadessa, Salvatore; Chiarolanza, I.; Ruocco, L.; Cuomo, Giovanna; Maresca, L.; Leonardo, G.; Valentini, G.
ELF TEST: A PROMISING SURROGATE OUTCOME MEASURE IN SYSTEMIC SCLEROSIS	1-gen-2011	G., Abignano; Cuomo, Giovanna; Buch, M.; Rosenberg, W. M.; Valentini, G.; Emery, P.

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 641 a 660 di 2.299

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext2298
open1